Strides' US Revenues Soar, Recovery Strategy ‘Executing To Plan’
Strides Pharma “very confident” about future after Indian generic company’s fourth-quarter US revenues rocketed 181% and EBITDA margins beat market expectations.

Strides Pharma “very confident” about future after Indian generic company’s fourth-quarter US revenues rocketed 181% and EBITDA margins beat market expectations.